Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in uniQure N.V., Viridian Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how uniQure N.V., Viridian Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About uniQure N.V., Viridian Therapeutics and Inc.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Latest Biotechnology and uniQure N.V., Viridian Therapeutics, Inc. Stock News

As of July 1, 2026, uniQure N.V. had a $3.1 billion market capitalization, compared to the Biotechnology median of $294.0 million. uniQure N.V.’s stock is up 84.5% in 2026, down 10.1% in the previous five trading days and up 224.03% in the past year.

Currently, uniQure N.V. does not have a price-earnings ratio. uniQure N.V.’s trailing 12-month revenue is $18.1 million with a % net profit margin. Year-over-year quarterly sales growth most recently was 125.0%. Analysts expect adjusted earnings to reach $-3.594 per share for the current fiscal year. uniQure N.V. does not currently pay a dividend.

As of July 1, 2026, Viridian Therapeutics, Inc. had a $2.0 billion market cap, putting it in the 54th percentile of all stocks. Viridian Therapeutics, Inc.’s stock is down 38.6% in 2026, up 9.8% in the previous five trading days and up 32.19% in the past year.

Currently, Viridian Therapeutics, Inc. does not have a price-earnings ratio. Viridian Therapeutics, Inc.’s trailing 12-month revenue is $70.9 million with a -508.5% net profit margin. Year-over-year quarterly sales growth most recently was 0.0%. Analysts expect adjusted earnings to reach $-3.783 per share for the current fiscal year. Viridian Therapeutics, Inc. does not currently pay a dividend.

How We Compare uniQure N.V., Viridian Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at uniQure N.V., Viridian Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

uniQure N.V., Viridian Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
uniQure N.V.	QURE	F
Viridian Therapeutics, Inc.	VRDN	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

uniQure N.V. has a Value Score of 1, which is Ultra Expensive. Viridian Therapeutics, Inc. has a Value Score of 6, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither uniQure N.V., Viridian Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if uniQure N.V., Viridian Therapeutics or Inc. is the better investment when it comes to value.

uniQure N.V., Viridian Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
uniQure N.V.	QURE	F
Viridian Therapeutics, Inc.	VRDN	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

uniQure N.V. has a Growth Score of 4, which is Very Weak. Viridian Therapeutics, Inc. has a Growth Score of 7, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither uniQure N.V., Viridian Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if uniQure N.V., Viridian Therapeutics or Inc. is the better investment when it comes to sustainable growth.

uniQure N.V., Viridian Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
uniQure N.V.	QURE	D
Viridian Therapeutics, Inc.	VRDN	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

uniQure N.V. has a Earnings Estimate Score of 35, which is Negative. Viridian Therapeutics, Inc. has a Earnings Estimate Score of 56, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither uniQure N.V., Viridian Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if uniQure N.V., Viridian Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other uniQure N.V., Viridian Therapeutics and Inc. Grades

In addition to Growth, Value and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether uniQure N.V., Viridian Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, uniQure N.V., Viridian Therapeutics or Inc. Stock?

Overall, uniQure N.V. stock has a Value Score of 1, Growth Score of 4 and Estimate Revisions Score of 35.

Viridian Therapeutics, Inc. stock has a Value Score of 6, Growth Score of 7 and Estimate Revisions Score of 56.

Comparing uniQure N.V., Viridian Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.